Clinical Trials Logo

Clinical Trial Summary

This is an open-label, single arm, non-randomized safety and efficacy study, where participants with Type-1 diabetes will receive the Sernova Cell Pouch™ implanted in the subcutaneous site, two to approximately twelve weeks prior to transplantation of islets into the Cell Pouch™. The primary objective of this study is to assess the safety of the Sernova Cell Pouch™ in adult participants with Type-1 diabetes receiving islet transplantation for the first time. Secondary objectives are the following: 1. To determine the proportion of subjects implanted with the Cell Pouch™ and transplanted with islets into the Cell Pouch™ who achieve and maintain insulin independence after islet transplantation. 2. To obtain preliminary data on the efficacy of the Cell Pouch™ to maintain adequate immunological protection against both allo- and autoimmunity of islet transplant recipients. 3. To determine through retrospective analysis comparative metabolic function and engraftment efficiency using patients undergoing standard intraportal islet transplantation under the current alemtuzumab standard of care protocol.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01652911
Study type Interventional
Source University of Alberta
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date June 2012
Completion date March 2016

See also
  Status Clinical Trial Phase
Completed NCT05160142 - Diabetes Inspired Culinary Education Early Phase 1
Withdrawn NCT05035368 - Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes Phase 2
Completed NCT01928329 - A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes Phase 2
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Completed NCT00999375 - Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF) Phase 2
Completed NCT04279613 - A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 Phase 1
Not yet recruiting NCT02117518 - Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients N/A
Withdrawn NCT01477476 - Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes Phase 2
Terminated NCT01308437 - Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics Phase 3
Completed NCT06242548 - How Type I Diabetes Responds to Different Diets (Normoglucidic or Ketogenic) During Physical Activity at Altitude N/A
Completed NCT00351650 - Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan N/A
Withdrawn NCT00361608 - Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device N/A
Terminated NCT03653533 - Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump N/A
Completed NCT00340639 - Management of Type 1 Diabetes Among Adolescents N/A
Completed NCT02634216 - Effects of Capros in Patients With Type-1 Diabetes N/A
Completed NCT02002130 - The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes Phase 1
Withdrawn NCT01623388 - Epigenetic Modifications of Diabetes Mellitus Type I N/A
Completed NCT02612493 - Obesity and Metabolic Surgery in Patients With Type I Diabetes N/A
Completed NCT01843114 - Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects N/A
Withdrawn NCT01398670 - Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics Phase 3